Literature DB >> 2868751

The role of a questionnaire and four biochemical markers to detect cancer risk in a symptomatic population.

E M Chisholm, R J Marshall, D Brown, E H Cooper, G R Giles.   

Abstract

The roles of a self-completed symptom questionnaire and four biochemical markers of disease were assessed to determine risk for gastric and colorectal cancer from within a hospital population and a random population. Eight-six patients with cancer, 168 subjects with benign conditions of the stomach and large bowel and 720 individuals from the community at large were investigated. Multivariate analyses of the questionnaire and biochemical data were performed individually and in combination using a data set comprising 54 cancer subjects, 80 patients with benign disease and 200 random individuals. The most favourable predictive equation derived was then applied to the remaining data set to determine its efficacy. In the primary analyses the questionnaire data identified 32 (60%) cancers successfully and using the biochemical markers alone 36 (67%) patients were also correctly classified as cancer bearing. However, the combination of the questionnaire and marker data improved the sensitivity for cancer to 50 cancers detected (92%) (P less than 0.02). Using the predictive equation from this combination of data to identify risk in the second data set 28/32 (88%) cancers were correctly identified with only an 11% false positive rate. An 18 month follow-up for the non-cancer group has to date revealed only one cancer (ca. pancreas). In this limited study, multivariate analysis of questionnaire and biochemical marker data does successfully identify individuals at "high risk' of harbouring gastric or colorectal cancer within a symptomatic population and may have a role in determining priority for investigation for a symptomatic individual.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2868751      PMCID: PMC2001465          DOI: 10.1038/bjc.1986.8

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  An analysis of bowel habit and its significance in the diagnosis of carcinoma of the colon.

Authors:  I S Jones
Journal:  Am J Proctol       Date:  1976-06

2.  An automated method for the determination of serum -glutamyltranspeptidase.

Authors:  J P Haesen; G T Berends; H A Zondag
Journal:  Clin Chim Acta       Date:  1972-03       Impact factor: 3.786

3.  On the use and computation of likelihood ratios in clinical chemistry.

Authors:  A Albert
Journal:  Clin Chem       Date:  1982-05       Impact factor: 8.327

4.  A study in general practice of the symptoms and delay patterns in the diagnosis of gastrointestinal cancer.

Authors:  D B Macadam
Journal:  J R Coll Gen Pract       Date:  1979-12

5.  Validation of a self administered questionnaire to elicit gastrointestinal symptoms.

Authors:  E M Chisholm; F T de Dombal; G R Giles
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-15

6.  Delay in diagnosis and treatment of symptomatic colorectal cancer.

Authors:  H W Holliday; J D Hardcastle
Journal:  Lancet       Date:  1979-02-10       Impact factor: 79.321

7.  Acute-phase reactant proteins and carcinoembryonic antigen in cancer of the colon and rectum.

Authors:  C Walker; B N Gray
Journal:  Cancer       Date:  1983-07-01       Impact factor: 6.860

8.  Value of plasma alpha-1-acid glycoprotein assay in the detection of human colorectal cancer: comparison with carcinoembryonic antigen.

Authors:  C Y Chu; L T Lai; H P Pokala
Journal:  J Natl Cancer Inst       Date:  1982-01       Impact factor: 13.506

9.  Acute-phase reactant protein profiles: an aid to monitoring large bowel cancer by CEA and serum enzymes.

Authors:  A M Ward; E H Cooper; R Turner; J A Anderson; A M Neville
Journal:  Br J Cancer       Date:  1977-02       Impact factor: 7.640

10.  Plasma protein profiles and prognosis in gastric cancer.

Authors:  S A Rashid; J O'Quigley; A T Axon; E H Cooper
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.